nanotech investing Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
nanotech investing Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
nanotech investing Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
nanotech investing Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
nanotech investing Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
nanotech investing Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
